HR Execs on the Move

Albireo Pharma

www.albireopharma.com

 
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo`s lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo`s clinical pipeline also includes two Phase 2 product candidates. Albireo`s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Brian DiMarco
Senior Director, Marketing Profile
Kosta Haveles
Senior Director, Talent Acquisition Profile

Similar Companies

CareFirst Urgent Care

Quality medical attention and care when you need it. All locations offer PCR, Rapid, Antinbody, and Rapid Antibody testing. Open 8am to 8pm, 7 days a week!

Southmedic

Established in 1983 Southmedics Domestic Division is one of the largest independent distributors of operating room products in Canada with a dynamic and efficient sales force from coast to coast. We specialize in selling surgical and specialty operati...

Zynex Medical

Zynex, Inc. is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management, physical rehabilitation, neurological diagnosis and cardiac monitoring.

Berg Pharma

Berg Pharma focuses research on understanding how alterations in metabolism relate to disease onset. The company has a deep pipeline of early-stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with use of the Berg Interrogative Biology™ discovery platform that translates biological output into therapeutic candidates, Berg Pharma is well positioned for rapid commercialization of its intellectual capital.